OncoMatch/Clinical Trials/NCT03535545
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
Is NCT03535545 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies [68Ga]CBP8 for pulmonary fibrosis.
Treatment: [68Ga]CBP8 — The goal of this study is to investigate the safety of \[68Ga\]CBP8 and its efficacy to detect collagen deposition in pulmonary fibrosis.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Small Cell Lung Cancer
Disease stage
Required: Stage IIIA
Demographics
Lab requirements
Kidney function
egfr of less than 30 ml/min/1.73 m2 within the past 90 days for group 4 subjects; history of chronic kidney disease for subjects in groups 1-3 and 5
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT03535545 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage IIIA is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify